3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
32
Lymphoma
9
Leukemia
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Leukemia, B-Cell
3
Waldenstrom Macroglobulinemia
2
Neoplasms
2
Stomach Neoplasms
1
Hodgkin Disease
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Chlorambucil
×
Clear all
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts
NCT01657955
2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3
Unknown
96 enrolled